#SFHS2608154AOrder of April 8, 2026, Modifying the List of Reimbursable Pharmaceutical Specialties for Social Insureds
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This law updates the list of drugs covered by social insurance in France. It specifically includes certain medications used for epilepsy, osteoporosis, and other conditions, defining conditions under which they are reimbursable. Pharmaceutical companies and healthcare providers should review these changes to ensure compliance with reimbursement policies.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Updates the list of reimbursable medications for social insureds.
- Includes specific medications for epilepsy and osteoporosis.
- Defines reimbursement conditions for included medications.
Obligations
What this law requires
Update reimbursement systems to include Brivaracetam Zentiva (25mg, 50mg, 75mg, 100mg tablets) as reimbursable medications for partial seizures with or without secondary generalization in adults and adolescents aged 16+ with epilepsy, and in children aged 2-15 with epilepsy
Update reimbursement systems to include Fampridine Sandoz LP and Fampridine Zentiva LP (10mg extended-release tablets) as reimbursable medications, limited to therapeutic indications specified in the market authorization approval as of the publication date
Update reimbursement systems to include Furosemide Teva Sante (500mg tablets) as a reimbursable medication within the social insurance formulary
Update reimbursement systems to include Zolestad (zoledronic acid 5mg/100ml infusion) as reimbursable for male osteoporosis, post-menopausal osteoporosis (with specific T-score and risk factor criteria), corticosteroid-associated osteoporosis, and Paget's disease, only within defined clinical indications
Ensure Brivaracetam Zentiva reimbursement is limited exclusively to combination therapy for partial seizure treatment in specified age groups (16+ adults/adolescents and children 2-15 years)